Abstract
Low-density lipoprotein (LDL) cholesterol lowering with statins have had a profound impact on cardiovascular (CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of high-density lipoproteins (HDL) may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and clinical events has fueled considerable debate as to whether attempts to target HDL will be of clinical benefit or futility. This review will reflect on challenges faced in developing new effective HDL targeted therapies.
Keywords: Atherosclerosis, high-density lipoproteins, lipids, risk factors.
Current Vascular Pharmacology
Title:Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?
Volume: 12 Issue: 4
Author(s): Stephen J. Nicholls, Jordan Andrews and MyNgan Duong
Affiliation:
Keywords: Atherosclerosis, high-density lipoproteins, lipids, risk factors.
Abstract: Low-density lipoprotein (LDL) cholesterol lowering with statins have had a profound impact on cardiovascular (CV) event rates and accordingly have become an integral component of strategies designed to reduce CV risk. The finding of a residual clinical risk, despite LDL cholesterol lowering, supports the need to develop additional therapeutic strategies for CV prevention. Numerous lines of evidence suggest that targeting the protective properties of high-density lipoproteins (HDL) may be beneficial. Disappointing results from recent reports of HDL genetics and raising agents and clinical events has fueled considerable debate as to whether attempts to target HDL will be of clinical benefit or futility. This review will reflect on challenges faced in developing new effective HDL targeted therapies.
Export Options
About this article
Cite this article as:
Nicholls J. Stephen, Andrews Jordan and Duong MyNgan, Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/1570161112999140411131155
DOI https://dx.doi.org/10.2174/1570161112999140411131155 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidant Properties of Hydroxycinnamic Acids: A Review of Structure- Activity Relationships
Current Medicinal Chemistry Bergamot (Citrus bergamia Risso) Flavonoids and Their Potential Benefits in Human Hyperlipidemia and Atherosclerosis: an Overview
Mini-Reviews in Medicinal Chemistry Therapeutic Approaches in Vascular Repair Induced by Adult Bone Marrow Cells and Circulating Progenitor Endothelial Cells
Current Pharmaceutical Design The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews ULK1 Plays a Critical Role in AMPK-Mediated Myocardial Autophagy and Contractile Dysfunction following Acute Alcohol Challenge
Current Pharmaceutical Design Anti-hyperglycemic Potential of Natural Products
Mini-Reviews in Medicinal Chemistry Screening of Antioxidant, Antimicrobial Activities and Chemical Contents of Edible Mushrooms Wildly Grown in the Black Sea Region of Turkey
Combinatorial Chemistry & High Throughput Screening Tea Consumption and Risk of Ischemic Stroke: a Brief Review of the Literature
Current Pharmaceutical Biotechnology Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents
Current Pharmaceutical Design Fetal and Early-Postnatal Developmental Patterns of Obese-Genotype Piglets Exposed to Prenatal Programming by Maternal Over- and Undernutrition
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Pharmacotherapy in Cardiac Ion Channelopathies
Current Vascular Pharmacology Transplantation of Adipose Tissue-Derived Stem Cells for Treatment of Focal Cerebral Ischemia
Current Neurovascular Research Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Sesbania: A Prospective Candidate to be Excavated for Anticancer Drugs
The Natural Products Journal The ATP-Binding Cassette Transporter Subfamily A Member 1 (ABC-A1) and Type 2 Diabetes: An Association Beyond HDL Cholesterol
Current Diabetes Reviews Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design Overview of Therapeutic Potential of Rapamycin for Coronary Artery Diseases in the Era of the Drug-Eluting Stent
Vascular Disease Prevention (Discontinued) Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Renal Protective Effect of Metabolic Therapy in Patients with Coronary Artery Disease and Diabetes: From Bench to Bed Side
Current Pharmaceutical Design